+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Leukemia Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4591691
  • Report
  • February 2020
  • Region: Global
  • 120 pages
  • Mordor Intelligence


  • Amgen Inc.
  • AstraZeneca plc
  • F. Hoffmann-La Roche Ltd
  • Incyte Corp
  • Johnson & Johnson
  • Novartis International AG
  • MORE
The leukemia therapeutics market is mainly driven by the rising burden of leukemia cases, high unmet medical need for cancer therapy and rising investment in healthcare sectors. According to the American Cancer Society, in the United States there were approximately 61,780 new cases of leukemia in 2019.

Among them, the number of new cases of acute myeloid leukemia (AML) were around 21,450. AML is thus considered as one of the most common types of leukemia in adults. Hnece the overall statistics shows that there is a huge number of people that are prone to suffer from leukemia, and which may directly impact the growth of the market in the forecast period.

Key Market Trends

Chemotherapy is Expected to Register a Significant Growth in the Forecast Years

Based on the treatment type, it is segmented into Chemotherapy, Immunotherapy, Targeted Therapy, and Others. The primary key factor contributing to the growth of the chemotherapy segment is the rising incidence of leukemia cases. According to the American Cancer Society, in 2019, there was around 22,840 death from leukemia in the United States, that has been reported and leading to the overall growth of the market.

Many companies are also focusing on developing breakthrough products for the treatment of Leukemia in order to maintain their competitive advantage and penetrate new regional markets. Chemotherapy is thus considered as the main treatment option for most individuals with Leukemia. Additionally, the increase in funding for companies involved in the research related to leukemia is expected to boost the studied market.

North America Holds the Largest Share in the Leukemia Therapeutics Market

The leukemia therapeutics market holds the largest share in the North America region due to the presence of high incidence rate, and advancements in the treatment of leukemia. According to American Cancer Society estimates, there were around 10,920 deaths due to acute myeloid leukemia in the United States in the year 2019. The statistics involve a large percentage of the adult population and they require proper medical treatment to increase their life expectancy.

in addition, Europe and the Asia Pacific are followed next after North America owing to the presence of a diversified patient pool and emerging economies in these regions.

Competitive Landscape

The leukemia therapeutics market is competitive and many of the global players are into the market. For instance - Amgen Inc, AstraZeneca plc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Incyte Corp, Johnson & Johnson, Novartis, Pfizer Inc and Sanofi. are providing these products across the globe. Product approvals are a key strategy adopted by key players in order to enhance their dominance in this market.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • Amgen Inc.
  • AstraZeneca plc
  • F. Hoffmann-La Roche Ltd
  • Incyte Corp
  • Johnson & Johnson
  • Novartis International AG
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study




4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Leukemia Cases
4.2.2 High Unmet Need for Cancer Therapy
4.2.3 Rising Investment in Healthcare Sector
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.3.2 Stringent Regulatory Scenario
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5.1 By Treatment Type
5.1.1 Chemotherapy
5.1.2 Immunotherapy
5.1.3 Targeted Therapy
5.1.4 Others
5.2 By Type of Leukemia
5.2.1 Acute Lymphocytic Leukemia
5.2.2 Acute Myeloid Leukemia
5.2.3 Chronic Lymphocytic Leukemia
5.2.4 Chronic Myeloid Leukemia
5.2.5 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America


6.1 Company Profiles
6.1.1 Amgen Inc.
6.1.2 AstraZeneca plc
6.1.3 Bristol-Myers Squibb Company
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Incyte Corp
6.1.6 Johnson & Johnson
6.1.7 Novartis International AG
6.1.8 Pfizer Inc.
6.1.9 Sanofi S.A.

Note: Product cover images may vary from those shown
  • Amgen Inc.
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Incyte Corp
  • Johnson & Johnson
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
Note: Product cover images may vary from those shown